The FDA has approved new agents in ovarian cancer and non–small cell lung cancer and paved the way for novel antibody-drug conjugate developments.

Dedicated to the future of cancer treatment, this topic covers emerging targeted and immunotherapeutic approaches in solid tumors and hematologic ...

CK Wang, MD, chief medical officer of COTA, highlights how a lack of screening tools and declining ob-gyn pipeline can compound historical disparities seen in Black women's access to care.

In a Phase Ia trial in ovarian cancer, a strong neutralizing antibody response correlated with better disease control and ...

Facility-level disparities in adopting minimally invasive interval debulking surgery for ovarian cancer highlight urgent ...

To address this challenge, CTMC has established a patient material bank, enabling early-stage process development with clinically relevant samples. This resource also supports continuous process ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | Merck's cancer superstar Keytruda has not yet been able to add an ovarian ...

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of ...

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination ...

First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an ...

In this video, Ursula A. Matulonis, MD, shares that although data from the REFRaME-O1 trial of luveltamab tazevibulin were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer ...

The U.S. Federal Drug Administration (FDA) has granted Incyclix Bio Fast Track designation for INX-315 to treat ...